Psoriasis

This study tests a new medicine called ORKA-001 for adults with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly patches. About 160 participants will receive either the drug or a placebo to see if it can completely clear the skin by week 16. The goal is to…

This study is testing the long-term safety and effectiveness of a drug called ORKA-001 for people with moderate-to-severe plaque psoriasis. It is an open-label extension, meaning everyone gets the drug, and it includes 240 adults who already completed a previous trial with ORKA-0…

This Phase 2 trial tests whether the oral drug RAP-103 can improve skin clearance and quality of life in people with moderate to severe psoriasis. About 90 adults aged 18 to 70 will take either a daily or twice-daily dose of RAP-103 or a placebo for 8 weeks. The study measures ho…

This phase 3 study tests whether the experimental drug WD-890 can safely improve skin clearance in adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive either WD-890 or a placebo tablet daily for up to 52 weeks. The main goals are to see …

This study follows 700 adults with moderate-to-severe plaque psoriasis who are already prescribed risankizumab by their doctor. Researchers will track changes in quality of life, including skin symptoms and daily impacts, over up to 2.5 years. The goal is to see how well the drug…

This phase 3 trial tests whether the drug bimekizumab can clear or nearly clear the pustules and skin lesions of palmoplantar pustulosis (PPP) on the hands and feet. About 320 adults with moderate to severe PPP will receive either bimekizumab or a placebo for 16 weeks, with an op…

This Phase 2 trial tests an experimental oral drug called D-2570 in 75 adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive either D-2570 or a placebo tablet for 12 weeks. The main goal is to see if the drug can achieve at least a 90% imp…

This study tests a daily pill called deucravacitinib in teenagers aged 12 to 18 with moderate to severe plaque psoriasis. About 366 participants will receive either the drug or a placebo. The main goals are to see if the drug improves skin clearance by at least 75% and reduces ov…

This phase 3 trial tests whether zasocitinib, an oral medication, can safely and effectively treat moderate-to-severe plaque psoriasis in children and teens aged 4 to 17. The study involves 110 participants and lasts up to 4 years. In the first part, some receive the drug and oth…

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This study tests the long-term safety of deucravacitinib compared to ustekinumab in about 3,040 adults with moderate-to-severe plaque psoriasis who also have heart risk factors like smoking, high blood pressure, or diabetes. Participants will receive one of the two medications an…

This study tests an experimental drug called ponesimod in 300 adults with moderate-to-severe plaque psoriasis. The goal is to see if it is safe and helps control the disease. Participants take the drug and are monitored for side effects and skin improvement.

This study watches 200 adults with moderate-to-severe plaque psoriasis who have never taken a biologic before. They are starting treatment with guselkumab, and researchers will track how many continue the drug for two years. The goal is to see how well people stick with this trea…

This study tests a drug called deucravacitinib in children and teens aged 4 to 18 with moderate to severe plaque psoriasis. The trial will measure how the drug works in the body, how well it clears psoriasis, and its safety over up to 5 years. Participants are randomly assigned t…

This study looks at how the drug tildrakizumab changes immune cells in the skin and blood of people with moderate-to-severe psoriasis. Ten adults will be treated and monitored for three months. The goal is to see how the drug reduces psoriasis severity and what happens to immune …

This study tests how guselkumab, a drug that blocks IL-23, affects immune cells in scalp psoriasis lesions. Ten adults with moderate-to-severe scalp psoriasis will receive treatment and have their scalp severity scores measured before and during treatment. The goal is to understa…

This Phase 3 trial is testing whether a new drug called QL2106 works as well as the approved medication Tremfya for people with moderate to severe plaque psoriasis. About 318 participants will receive either QL2106 or Tremfya injections over several months. The main goal is to se…

This study looks at how deucravacitinib, a drug that blocks a specific immune signal (TYK2), changes immune cells in the skin and blood of people with moderate-to-severe psoriasis. About 25 adults will take the drug and be monitored for improvements in their psoriasis symptoms. T…

This study tests a cream called delgocitinib for people with mild to severe palmoplantar pustulosis, a skin condition causing painful pus-filled blisters on hands and feet. About 135 adults will apply the cream twice daily for 16 weeks. The main goal is to see if the cream reduce…

This study tests whether adding a Mediterranean diet (rich in olive oil, nuts, fish, and limited red meat) improves psoriasis symptoms in 36 adults who are about to start biologic therapy (Anti-IL-17 or Anti-IL-23 drugs). Participants are randomly assigned to either follow the di…

This study is testing whether adding the weight-loss drug tirzepatide to the standard psoriasis medication ixekizumab helps people with moderate-to-severe plaque psoriasis who are also overweight or obese. About 200 adults will receive tirzepatide injections for up to 12 months. …

This early-stage study tests a new drug called S-4321 in 24 adults with autoimmune diseases like rheumatoid arthritis, psoriasis, lupus, or eczema. The goal is to check safety and how the drug affects the body. Participants receive multiple doses and are monitored for side effect…

This study tests a bone marrow transplant from a family donor for children under 21 with severe non-cancer blood disorders like sickle cell disease, bone marrow failure, or immune problems. The goal is to see if the transplant can replace the diseased cells with healthy donor cel…

This study tests a new medicine called bimekizumab against an existing one (ustekinumab) for children and teens aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see if bimekizumab works better at clearing skin symptoms. About 168 participants will receive inj…

This study follows 350 adults in France with moderate-to-severe plaque psoriasis who are starting deucravacitinib, a daily pill. Researchers will track how well the drug controls skin symptoms and improves quality of life over time in real-world settings, not a controlled lab env…

This study watches 200 adults with moderate to severe psoriasis who switch from ustekinumab to guselkumab in everyday medical practice. Researchers track how well the new drug clears skin symptoms and check for side effects over 52 weeks. The goal is to see if guselkumab works sa…

This study compares methotrexate alone versus methotrexate plus the antidepressant escitalopram in 40 adults with moderate to severe psoriasis and depression or anxiety. Over six months, researchers will measure skin improvement and mental health changes to see if the combination…

This Phase 3 trial tests D-2570, a new daily pill, in 477 adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive D-2570, an active comparator (BMS-986165), or a placebo. The study measures how well the drug clears skin and improves quality …

This study tests a drug called picankibart in 60 adults with moderate-to-severe palmoplantar pustulosis, a painful skin condition causing pus-filled blisters on hands and feet. Participants receive injections of picankibart over nearly a year. The goal is to see if it reduces the…

This study compares the effectiveness and safety of different doses and schedules of guselkumab in 400 Chinese adults with moderate to severe plaque psoriasis. Participants will receive either a high dose, an extended-interval dose, or the standard dose. The goal is to find the b…

This study tests a new biologic drug called Xeligekimab in 10 adults with moderate to severe palmoplantar pustulosis (PPP), a chronic skin disease causing painful blisters and scales on the palms and soles. The goal is to see if the drug can reduce symptoms and improve quality of…

This phase 2 trial tests an injection called TQH2929, a lab-made antibody that blocks inflammation, in 36 adults having a sudden, severe flare of generalized pustular psoriasis (GPP). Half get the drug, half get a placebo. The main goal is to see if the drug clears pustules withi…

This study tests whether a daily magnolia bark supplement (Viv) can reduce immune-related blood markers in adults with psoriasis. One hundred participants will take either the supplement or a placebo for three months. Researchers will measure changes in inflammatory proteins and …

This study tracks the safety and effectiveness of the drug Cosentyx (secukinumab) in Korean patients with hidradenitis suppurativa, pediatric plaque psoriasis, or juvenile idiopathic arthritis. Researchers will monitor 76 participants for side effects and how well the drug works …

This study tests whether measuring biologic drug levels in the blood can help doctors adjust doses for people with psoriasis. About 210 adults on certain biologics will either get dose advice based on blood tests or continue standard care. The goal is to maintain disease control …

This phase 3 trial tests a cream made from plant compounds (total coumarins) for treating psoriasis vulgaris. 300 adults will apply the cream or a placebo twice daily for 8 weeks. Researchers will check if the cream improves skin symptoms and quality of life, and monitor for side…

This study looks at whether people with psoriasis who are doing very well on the drug guselkumab (Tremfya) can safely wait longer than the usual 8 weeks between injections. Researchers will track 100 adults whose doctors have already extended their dosing intervals to see how the…

This study tests whether adding semaglutide (a drug used for diabetes and weight loss) to a standard topical cream can improve psoriasis symptoms and reduce body-wide inflammation. About 62 adults with plaque psoriasis who are overweight or have type 2 diabetes will receive eithe…

This study compares two treatments for mild-to-moderate plaque psoriasis: acupuncture combined with a Chinese herbal cream versus acupuncture combined with a standard medicated cream (calcipotriol). About 28 adults with psoriasis on skin, scalp, or nails will be enrolled. Researc…

This Phase 3 trial tests an oral drug called ICP-488 in 383 adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive either the drug or a placebo for 16 weeks. The main goal is to see if the drug can significantly clear or nearly clear the sk…

This study tests a special hydrogel patch applied daily to toenails for three months. It is designed for people with nail fragility, fungal infections, or nail psoriasis. The trial includes 72 adults and compares the active patch to a placebo to see if it safely improves nail hea…

This study compares two drugs, methotrexate and apremilast, to see which works better for moderate to severe plaque psoriasis. About 106 adults with psoriasis will take one of the drugs for 12 weeks. The goal is to find which treatment reduces skin symptoms more effectively.

This phase 2 trial tests an experimental oral drug called ICP-332 against a placebo in 172 adults with moderate-to-severe plaque psoriasis. Participants take the drug or placebo daily for 12 weeks. The main goal is to see if at least 75% of skin symptoms improve. If it works, ICP…

This study tests whether applying a solution of Lactobacillus plantarum, a beneficial bacteria from healthy skin, to psoriasis patches can improve the condition. 184 adults with mild-to-moderate psoriasis will apply the bacteria or an inactive version daily for two months. The go…

This study tests a drug called picankibart in teenagers aged 12 to 18 with moderate-to-severe plaque psoriasis. Half get the drug, half get a placebo, and researchers check if their skin clears up after 16 weeks. The goal is to see if it's safe and works better than a dummy treat…

This Phase 1 trial tests a new biosimilar called CKD-704, which is designed to be a more affordable copy of the psoriasis drug Skyrizi (risankizumab). The study involves 213 healthy adults who will receive a single dose of either CKD-704, the EU-approved Skyrizi, or the US-licens…

This study tests an experimental drug called D-2570 against a placebo in 390 adults with moderate to severe plaque psoriasis. The main goal is to see if the drug can clear at least 90% of skin plaques after 16 weeks of treatment. Participants must have stable psoriasis for at lea…

This study tests a daily pill called ivarmacitinib for palmoplantar pustulosis (PPP), a chronic skin condition causing painful blisters on hands and feet. Sixty adults who haven't improved with other treatments will take the pill for 12 weeks. Researchers will check if symptoms l…

This study compares two oral medications, methotrexate and tofacitinib, to see which is more effective at reducing psoriasis plaques. It involves 75 adults with moderate to severe chronic plaque psoriasis who have not responded well to topical treatments. The main goal is to meas…

This study follows 200 Italian patients with moderate-to-severe psoriasis who are already taking deucravacitinib, a daily pill that calms the immune system. Researchers will track how well the drug controls skin symptoms, its side effects, and how it affects quality of life in re…

This study tests whether early use of the drug bimekizumab can delay or prevent chronic inflammation in people with mild plaque psoriasis. 40 adults with recent-onset or long-standing mild psoriasis will receive either bimekizumab injections or a topical steroid cream. The goal i…

This study tests an experimental oral drug called a TYK2 inhibitor for people with moderate to severe plaque psoriasis. About 140 adults will receive either the drug or a placebo for 12 weeks. The main goal is to see if the drug can reduce psoriasis severity by at least 75%.

This Phase 2 trial is testing a new biologic drug called HB0017 in 200 adults with moderate to severe plaque psoriasis. Participants receive different doses and schedules of the injection to see how well it clears skin plaques and how safe it is. The study is double-blind and ran…

This early-stage study tests whether adding daily probiotics to weekly methotrexate can improve psoriasis symptoms and gut bacteria in newly diagnosed adults. 24 participants will either get probiotics plus methotrexate or methotrexate alone for 4 months. Researchers will compare…

This study tests an experimental capsule called CS32582 in adults with moderate-to-severe plaque psoriasis. The trial has two parts: a short 4-week dose-finding phase and a longer 12-week phase to see how well the drug clears skin and whether it is safe. About 220 participants wi…

This study tests whether using a person's unique biomarkers to choose their biologic treatment works better than the standard approach for psoriasis and psoriatic arthritis. About 50 adults in Taiwan will be randomly assigned to either a personalized selection group or a standard…

This Canadian study tests whether adding two questions about morning stiffness and lower back pain to a standard screening tool (PEST) can help dermatologists identify psoriatic arthritis earlier in people with moderate-to-severe plaque psoriasis. About 502 adults who are candida…

This early-stage study tests a new imaging agent called 18F-4FN for PET scans to safely detect inflammation in the body. It involves 55 adults with cancer who are on immunotherapy or have suspected inflammation. The goal is to see if this agent can highlight areas of inflammation…

This study tests whether a dermatologist's physical exam is better than a patient questionnaire at spotting psoriatic arthritis (PsA) in people with psoriasis. About 500 adults with psoriasis will be checked by both methods, then referred to a rheumatologist for a final diagnosis…

This study is testing a software tool called Belle.ai that uses artificial intelligence to help doctors diagnose common skin diseases. About 400 patients at dermatology clinics will have three photos taken of their skin condition. The AI will analyze the photos and suggest possib…

This study tests whether the drug guselkumab can prevent psoriatic arthritis in people with psoriasis who are at high risk. 176 adults with psoriasis and early signs of joint inflammation will receive either guselkumab or standard care. The goal is to see if the drug can stop art…

This study tests whether a mobile app that provides psychological tools can improve quality of life for people with eczema, psoriasis, or chronic hives. Participants use the app over 32 weeks to learn coping strategies and wellness tips. The goal is to see if this digital approac…

This study tests whether Mindfulness-Based Cognitive Therapy (MBCT) can reduce psychological distress and improve self-compassion in people with psoriasis. Researchers will enroll 128 adults with psoriasis who are experiencing emotional difficulties. Participants will either rece…

This study tests a new medicine called ORKA-002 for adults with moderate-to-severe plaque psoriasis. About 160 participants will receive either the drug or a placebo to see if it clears skin and is safe. The goal is to find the best dose and check for side effects over 16 weeks.

This study tests whether adding daily oral vitamin D3 to a standard steroid cream can improve mild to moderate psoriasis. About 24 adults will use the cream for 4 weeks, then be split into two groups: one gets vitamin D, the other a placebo, for 12 weeks. After that, everyone rec…

This study tests a group counseling program called Healing HEARTS to help people with conditions like obesity, skin disease, cancer, HIV, diabetes, or chronic pain deal with internalized stigma. Participants will either join the counseling program or a peer support group. The goa…

This study is testing a new laser called PALLAS to treat skin diseases like vitiligo, psoriasis, alopecia areata, and atopic dermatitis. About 50 people will receive UVB laser treatments twice a week for up to 3 months. The goal is to see if the laser improves the skin condition …

This study explores whether removing wheat and cow's milk from the diet can reduce inflammation and improve skin symptoms in people with mild-to-moderate psoriasis. 82 participants will follow either a wheat- and dairy-free diet or a control diet for 2 months, then some will be r…

This early-stage study tests an experimental oral drug, LPX-TI641, in 48 adults with atopic dermatitis (eczema) or psoriasis. The main goal is to check if the drug is safe and tolerable compared to a placebo over 28 days. Researchers will also measure how the drug moves through t…

This study looks at whether adding treadmill walking to a low-calorie diet can improve psoriasis and polycystic ovary syndrome (PCOS) in women. Forty obese women with both conditions will be split into two groups: one does diet plus walking, the other does diet only. The trial la…

This study tests an oral medication called roflumilast in 36 adults with moderate-to-severe plaque psoriasis. Over 12 weeks, researchers will measure how much the skin improves and check for side effects. The goal is to see if this drug can help reduce symptoms like redness, scal…

This early-stage study tests a new tablet called UA026 to see if it is safe and how the body processes it. It involves 124 people, including healthy volunteers and those with moderate to severe plaque psoriasis. The study is split into four parts to check different doses and the …

This study tests a new cream made with ceramide, coconut oil, and cholesterol to see if it improves skin hydration, redness, and itch in people with mild skin barrier problems like eczema, psoriasis, or dry skin. 26 adults will apply either the new cream or plain petrolatum twice…

This study aims to learn more about how diseases related to blood clots, the immune system, and blood vessels start and change over time. Researchers will enroll up to 1,000 people aged 5 and older, including those with these conditions, their healthy relatives, and healthy volun…

This study looks for better ways to detect lung inflammation and infections early in people who have received a stem cell transplant from a donor. About 40 participants aged 5 to 70 will get regular lung scans, breathing tests, blood draws, and a procedure where a tube collects f…

This study will use a new, more sensitive total-body PET scanner to measure inflammation in the skin, joints, and blood vessels of people with psoriasis. Researchers want to see if switching from a typical Western diet to a more balanced diet for 6 weeks can reduce that inflammat…

This study follows 2500 adults with moderate-to-severe plaque psoriasis who are starting a new advanced therapy. Researchers will check their progress at 16 and 24 weeks using questionnaires. The goal is to build a detailed picture of early treatment responses in real-world setti…

This study is collecting skin and blood samples from 830 people with chronic inflammatory skin diseases like psoriasis, eczema, and lupus. Researchers want to find biological markers that can predict how well a person will respond to treatment after one year. The goal is to move …

This study observes how people with psoriasis receive care in different countries. Researchers will collect data from routine doctor visits to understand treatment patterns, disease severity, and quality of life. The goal is to identify gaps in healthcare delivery and improve out…

This study aims to understand how the immune system and skin healing are connected in people with primary immunodeficiency, psoriasis, or eczema, as well as in healthy volunteers. Researchers will collect skin biopsies, blood samples, and optional skin swabs to analyze microbes a…

This study follows 2,500 adults with moderate-to-severe plaque psoriasis who are starting a new advanced therapy. Researchers will collect data at the start and after 2, 4, and 16 weeks to see how quickly the treatment works. The goal is to build a detailed picture of early treat…

This study collects biological samples—like blood, skin biopsies, and swabs—from people with or at risk for skin diseases, as well as healthy volunteers. Researchers will use these samples to study the causes of skin conditions and explore potential treatments. Up to 700 particip…

This study looks at 40 adults with psoriasis—some with joint pain (psoriatic arthritis) and some without—to compare immune signals in their blood and skin. Researchers want to understand why some people develop joint problems. Participants give blood and skin samples for lab anal…

This study is testing an educational tool designed for people with melanoma who also have an autoimmune disease and are considering treatment with immune checkpoint inhibitors. Researchers want to see if the tool is easy to use and helpful for both patients and healthcare provide…

This study looks at how weight loss (using tirzepatide) and a biologic drug (ixekizumab) affect the body in people with psoriatic arthritis who are overweight or obese. About 45 adults will receive one or both treatments. Researchers will take samples of skin, joint tissue, and f…

This study looks at the bacteria living on the skin of people with cutaneous T cell lymphoma, a rare type of skin cancer. Researchers will compare these bacteria to those on healthy people and people with other skin conditions like psoriasis. The goal is to understand if certain …

This study looks at how much of the drug bimekizumab passes into breast milk. Researchers will collect milk samples from 20 breastfeeding mothers with conditions like psoriasis or arthritis over several weeks. The goal is to understand potential exposure for nursing infants, not …

This study looks at how the Shingrix vaccine (for shingles) works in people with psoriasis or myelofibrosis who are taking drugs that weaken their immune system. Researchers will compare their immune response to that of similar patients not on these drugs. The goal is to understa…

This study looks at how abnormal blood vessel growth (angiogenesis) contributes to various skin diseases like rosacea, psoriasis, and certain tumors. Researchers will collect skin samples from 85 volunteers aged 16 and older to analyze markers of angiogenesis. The goal is to bett…

This study looks at inflammatory genes in people with psoriasis to better understand the disease. Researchers will take skin samples from 13 adults with psoriasis and measure genes linked to inflammation. The goal is to find markers that could help manage psoriasis in the future.

This study looks for gene markers that could predict how well a person with psoriasis will respond to certain FDA-approved drugs. About 56 participants will try two different psoriasis medications for 8 weeks each, while researchers take blood and skin samples. The goal is to mak…

This study collects skin samples from 500 people with conditions like acne, eczema, and psoriasis, as well as healthy volunteers. Researchers will analyze the samples to find biomarkers and gene patterns linked to inflammation. The goal is to better understand these skin diseases…

This study is testing a tool called B-COMPASS that uses a 22-question survey to predict whether people will follow their prescribed treatments. Researchers will enroll 3100 adults with cardiovascular, endocrine, immune, nerve, cancer, or rare diseases across Europe. The goal is t…

This pilot study is measuring prednisolone levels in 120 people with inflammatory diseases like thyroid eye disease, vasculitis, COPD, asthma, and others. Participants take high-dose prednisolone as part of their routine care, and researchers take timed blood samples to see how t…

This study aims to create a large collection of blood samples and medical information from 800 people with autoimmune or inflammatory skin diseases. Researchers will use these samples to find new biomarkers and better understand what causes these conditions. The goal is to help d…

This study examines whether biologic treatments for moderate-to-severe psoriasis increase the chance of developing or having a return of genital warts. Researchers will review past medical records and follow 600 adults for two years to compare different treatments. They will also…

This study looks at 320 adults who are about to start strong immune-suppressing therapy and have already had at least two COVID-19 shots. Researchers want to find out if giving a COVID-19 booster right before starting therapy or waiting six months provides better protection. Part…

This study is creating a large registry of 800 people receiving biologic medications for immune conditions like autoimmune diseases and primary immune deficiencies. Researchers will collect blood samples and health data to better understand how these treatments work and who respo…

This study looks at how well people with psoriasis respond when they need several different biologic treatments over time. Researchers will review medical records from 366 adults treated in NHS hospitals to see if each new treatment works as well as the first. No extra visits are…

This study is a registry that will follow about 200 people with generalized pustular psoriasis (GPP) across North America. Researchers want to learn more about how GPP develops, how it is managed, and what happens to patients over time. Participants will be under the care of a de…

This study follows 80 adults in Canada with moderate-to-severe psoriasis who are starting the drug tildrakizumab. Researchers want to see how the treatment affects quality of life and skin clearing over one year, especially in people with darker skin tones (Fitzpatrick type III a…

This research study collects health information from 10,000 people with brain inflammation conditions like Long COVID, ME/CFS, and autoimmune diseases. Participants use a smartphone app to share symptoms, health history, and wearable data. The goal is to find disease subtypes and…

This study looks at whether a gene called vaspin, which is linked to fat tissue, plays a role in psoriasis. Researchers will compare blood samples and gene patterns from 60 people with psoriasis to see if certain gene changes are tied to more severe disease. The goal is to better…

This study looks at how skin conditions related to cancer or cancer treatments affect the well-being of cancer patients and survivors. About 1,025 participants will fill out questionnaires about their skin condition. The goal is to better understand these effects and improve trea…

This study looks at how the body processes Hemay005 tablets in people with mild or moderate liver problems compared to those with normal liver function. The goal is to find the right dose for patients with liver issues. 24 adults with psoriasis will take a single dose and have th…

This study is tracking 1,000 adults with psoriasis to see how their skin condition relates to heart disease. Researchers will use blood tests and heart imaging to find early signs of heart problems. The goal is to better understand why people with psoriasis have higher rates of h…